FDA Recommends DEA Schedule Synthetic 7-OH as Controlled Substance, Citing Opioid Addiction Risk

Why it matters

The FDA's formal recommendation to schedule synthetic 7-OH could remove an entire category of concentrated kratom derivatives from the legal market — affecting millions of consumers who use these products and triggering a cascade of state-level regulatory actions.

The big picture

For years, the FDA distinguished between natural kratom leaf — which it advises against but has not scheduled — and synthetic 7-hydroxymitragynine (7-OH), a concentrated derivative far more potent than anything found in the plant. In July 2025, the agency made that distinction official policy by forwarding a scheduling recommendation to the DEA. The move came alongside new warning letters to seven companies and consumer education materials, signaling a coordinated federal enforcement push.

Key findings

• FDA recommended DEA classify certain concentrated 7-OH products under the Controlled Substances Act
• 7-OH can be more potent than morphine; the FDA called it a new opioid threat available in gas stations and vape shops
• The agency issued warning letters to seven companies selling 7-OH tablets, gummies, drink mixes, and shots
• FDA clarified the action targets synthetic 7-OH specifically — not natural kratom leaf products
• DEA has final scheduling authority and must complete a public rulemaking process before any scheduling takes effect

What they say

"7-OH is an opioid that can be more potent than morphine. We need regulation and public education to prevent another wave of the opioid epidemic," said FDA Commissioner Marty Makary, M.D., M.P.H.

Bottom line

The FDA has drawn a formal regulatory line between natural kratom and synthetic 7-OH — and is pushing the DEA to make concentrated 7-OH products illegal.